Skip navigation
Skip navigation

Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy

Drahos, Peter F; Searles, Andrew; Neville, Warwick; Doran, Evan; Henry, David A; Pekarsky, Brita; Faunce, Thomas

Description

On 1 January 2005, a controversial trade agreement entered into force between Australia and the United States. Though heralded by the parties as facilitating the removal of barriers to free trade (in ways not achievable in multilateral fora), it also contained many trade-restricting intellectual property provisions and others uniquely related to altering pharmaceutical regulation and public health policy in Australia. The latter appear to have particularly focused on the...[Show more]

dc.contributor.authorDrahos, Peter F
dc.contributor.authorSearles, Andrew
dc.contributor.authorNeville, Warwick
dc.contributor.authorDoran, Evan
dc.contributor.authorHenry, David A
dc.contributor.authorPekarsky, Brita
dc.contributor.authorFaunce, Thomas
dc.date.accessioned2009-04-20T05:41:10Z
dc.date.accessioned2010-12-20T06:03:05Z
dc.date.available2009-04-20T05:41:10Z
dc.date.available2010-12-20T06:03:05Z
dc.identifier.citationGlobalization and Health 15.1 (2005): 1-10
dc.identifier.issn1744-8603
dc.identifier.urihttp://hdl.handle.net/10440/82
dc.description.abstractOn 1 January 2005, a controversial trade agreement entered into force between Australia and the United States. Though heralded by the parties as facilitating the removal of barriers to free trade (in ways not achievable in multilateral fora), it also contained many trade-restricting intellectual property provisions and others uniquely related to altering pharmaceutical regulation and public health policy in Australia. The latter appear to have particularly focused on the world-respected process of federal government reimbursement after expert cost-effectiveness evaluation, popularly known as the Pharmaceutical Benefits Scheme ('PBS'). It remains uncertain what sort of impacts – if any – the Australia-United States Free Trade Agreement ('AUSFTA') will have on PBS processes such as reference pricing and their important role in facilitating equitable and affordable access to essential medicines. This is now the field of inquiry for a major three year Australian Research Council ('ARC')-funded study bringing together a team of senior researchers in regulatory theory from the Australian National University and pharmacoeconomics from the University of Newcastle. The project proposes to monitor, assess and analyse the real and potential impacts of the AUSFTA in this area, providing Australian policy-makers with continuing expertise and options. To the extent that the AUSFTA medicines provisions may represent an important precedent in a global strategy by industry on cost-effectiveness evaluation of pharmaceuticals, the study will also be of great interest to policy makers in other jurisdictions.
dc.format10 pages
dc.publisherBioMed Central
dc.rightsThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0)which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.sourceGlobalization and Health
dc.source.urihttp://www.globalizationandhealth.com/content/pdf/1744-8603-1-15.pdf
dc.subjectKeywords: essential drug; article; Australia; cost benefit analysis; cost effectiveness analysis; drug cost; drug industry; drug legislation; drug marketing; expert system; government regulation; health care access; health care policy; international cooperation; me
dc.titleAssessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy
dc.typeJournal article
local.description.refereedYes
local.identifier.citationvolume15
dcterms.dateAccepted2005-10-06
dc.date.issued2005-10-06
local.identifier.absfor180119
local.identifier.ariespublicationMigratedxPub13995
local.type.statusPublished Version
local.contributor.affiliationFaunce, Thomas A, ANU College of Law and Medical School
local.contributor.affiliationDrahos, Peter F, Research School of Pacific and Asian Studies, Regulatory Institutions Network Program
local.contributor.affiliationSearles, Andrew, Research School of Pacific and Asian Studies, Regulatory Institutions Network Program
local.contributor.affiliationNeville, Warwick, Research School of Social Sciences, Philosophy Program
local.contributor.affiliationDoran, Evan, University of Newcastle
local.contributor.affiliationHenry, David A, University of Newcastle
local.contributor.affiliationPekarsky, Brita, University of South Australia
local.bibliographicCitation.issue1
local.bibliographicCitation.startpage1
local.bibliographicCitation.lastpage10
local.identifier.doi10.1186/1744-8603-1-15
dc.date.updated2015-12-12T08:00:19Z
local.identifier.scopusID2-s2.0-29444443468
CollectionsANU Research Publications

Download

File Description SizeFormat Image
Faunce_Assessing2005.pdf287.84 kBAdobe PDFThumbnail


Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  19 May 2020/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator